Scientech Research LLC’s Recursion Pharmaceuticals RXRX Stock Holding History

Scientech Research LLC’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-26,902	Closed	-$82.6K	–	492
2026 Q1	$82.6K	Buy	26,902 +10,445	+63%	+$40.4K	0.07%	361
2025 Q4	$67.3K	Buy	16,457 +3,031	+23%	+$15K	0.04%	434
2025 Q3	$65.5K	Sell	13,426 -115,637	-90%	-$607K	0.02%	508
2025 Q2	$653K	Buy	+129,063	New	+$634K	0.16%	264
2024 Q4	–	Sell	-88,103	Closed	-$581K	–	820
2024 Q3	$581K	Sell	88,103 -52,192	-37%	-$374K	0.12%	343
2024 Q2	$1.05M	Buy	+140,295	New	+$1.22M	0.22%	171

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Scientech Research LLC's RXRX Position: Q2 2026 in Review

Scientech Research LLC sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 26,902 shares — an estimated $82.6K sold.

Scientech Research LLC first reported a position in RXRX in Q2 2024 and held it in 6 quarters. The position peaked at $1.05M in Q2 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Scientech Research LLC reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Scientech Research LLC sold 26,902 Recursion Pharmaceuticals shares in Q2 2026, an estimated $82.6K.
Scientech Research LLC first reported a position in Recursion Pharmaceuticals in Q2 2024 and held it in 6 quarters.
Scientech Research LLC's Recursion Pharmaceuticals position peaked at $1.05M in Q2 2024.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Scientech Research LLC's 13F filing for Q2 2026, filed 14 Aug 2026.